Vera Therapeutics

Our Company

Our mission is to change the standard of care for patients with immunologic and rare diseases. We are developing multiple novel biologic molecules toward this end.

Our lead late-stage clinical candidate is atacicept:

  • Fully humanized TACI-Fc fusion protein that inhibits the two cytokines, BAFF and APRIL, that cause B cells and plasma cells to produce disease-causing antibodies
  • Potential best- and first-in-class dual BAFF/APRIL B cell modulator for IgA Nephropathy (IgAN), a B cell-mediated kidney disease that often progresses to kidney failure despite optimized supportive care
  • Demonstrated sustained eGFR stabilization through 72 weeks in the ORIGIN Phase 2b clinical trial for IgAN
  • ORIGIN 3, a pivotal Phase 3 clinical trial, initiated June 2023
  • Target profile: at-home self-administration by subcutaneous once weekly autoinjector

We also hold worldwide global rights to MAU868:

  • A monoclonal antibody that neutralizes infection by blocking BK virus (BKV) binding to host cells
  • Phase 2 clinical trial showed MAU868 was well tolerated and showed clinically meaningful reductions in BK antiviral activity through 36 weeks in kidney transplant patients with BK viremia
  • No BK-specific treatment currently available
  • Target profile: monthly IV administration

Our Team

Marshall Fordyce, MD

CEO and Founder

Robert M. Brenner, MD

Chief Medical Officer

Lauren Frenz, MBA

Chief Business Officer

Sean Grant, MBA

Chief Financial Officer

David Johnson, MBA

Chief Operating Officer

William D. Turner

Chief Development Officer

Kelly Rauber

SVP, Human Resources

Julien E. Capers, JD

SVP, Legal

Tom Doan

SVP, Development Operations

Neeraj Pakala, PhD, MBA

SVP, Product Development and Manufacturing

Joseph Young, MBA

Chief Accounting Officer

Board of Directors

Michael M. Morrissey, PhD

President and CEO

Andrew Cheng, MD, PhD

President and CEO
Akero Therapeutics

Beth Seidenberg, MD

General Partner
Kleiner Perkins

Maha Katabi, PhD, CFA

General Partner
Sofinnova Investments

Patrick Enright, MBA

Managing Director
Longitude Capital

Scott Morrison

Former Partner and US Life Sciences Leader

Marshall Fordyce, MD

President and CEO
Vera Therapeutics

Kimball Hall

President and CEO
Innocoll Biotherapeutics